- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02869412
Computer-Based Behavior Change Guide in Increasing Physical Activity in Patients With Prostate Cancer Who Have Received Androgen Deprivation Therapy
A Physical Activity Behavior Change Guide for Prostate Cancer Patients (iTRAIN Study)
Study Overview
Status
Conditions
Detailed Description
PRIMARY OBJECTIVES:
I. Engage with prostate cancer patients (PCPs) who have received or are currently on androgen deprivation therapy (ADT) to develop a computer-based behavior change guide (BCG) for PCPs to provide fundamental information about benefits of exercise for their individual capabilities and goals and provide a personalized physical activity plan. (Development Phase) II. Engage with PCPs to understand what outcomes are most important to them related to becoming active (e.g., helped me manage side-effects of treatment, reduced fatigue) and develop measures to evaluate these patient-centered outcomes. (Development Phase) III. Evaluate the BCG in a study comparing the personalized computer-based BCG with physical activity recommendations provided via a passive website (American Cancer Society Guidelines on Nutrition and Physical Activity for Cancer Survivors) among PCPs who have received ADT. (Evaluation Phase)
OUTLINE:
DEVELOPMENT PHASE: Patients view mock-ups of the BCG web design on a computer, iPad, or printed color paper and provide feedback with a one-on-one interview or separately using the think/talk aloud method followed by a one-on-one interview. After completion of these design rounds, patients use the BCG website and provide individual feedback.
EVALUATION PHASE: Patients are randomized to 1 of 2 groups.
GROUP I: Patients use the BCG website which will collect personal information including individual health priorities/goals, demographics (i.e. age, ethnicity), health information (i.e. weight, height, cancer history, other health conditions), individual capabilities, physical activity level, and exercise preferences. Patients then receive a report with a personalized physical activity plan.
GROUP II: Patients use a passive website (American Cancer Society Guidelines on Nutrition and Physical Activity for Cancer Survivors).
After completion of study, patients are followed up at 2 months.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Oregon
-
Portland, Oregon, United States, 97239
- OHSU Knight Cancer Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Prostate cancer (PCa) diagnosis
- Able to read English on a computer screen
- Signed an Institutional Review Board (IRB)-approved informed consent
- EVALUATION PHASE
- Underactive (defined as physically active for less than 30 minutes per day fewer than 2 days per week)
- Access to a computer at home or public location
Exclusion Criteria:
- Non-English speaking subjects are excluded from this study; the website being developed will only be available in English
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Group I (BCG website)
Patients use the BCG website which will collect personal information including individual health priorities/goals, demographics (i.e.
age, ethnicity), health information (i.e.
weight, height, cancer history, other health conditions), individual capabilities, physical activity level, and exercise preferences.
Patients then receive a report with a personalized physical activity plan.
|
Ancillary studies
Other Names:
Ancillary studies
Use BCG website
Use passive website
|
|
Active Comparator: Group II (passive website)
Patients use a passive website (American Cancer Society Guidelines on Nutrition and Physical Activity for Cancer Survivors).
|
Ancillary studies
Other Names:
Ancillary studies
Use BCG website
Use passive website
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in self efficacy for exercise, assessed by the Self Efficacy for Exercise questionnaire (Evaluation Phase)
Time Frame: Baseline up to 2 months
|
For the qualitative characteristics collected, univariate summaries (e.g., frequency counts and proportions) will be calculated.
For quantitative characteristics, means, standard deviations, medians, and ranges will be computed.
The analysis will be conducted as an intent-to-treat efficacy assessment comparing the two interventions.
Analyses will examine changes between baseline and follow-up scores on outcome measures by group.
Comparisons will be conducted using Generalized Estimating Equations (GEE) with robust (sandwich) variance estimates.
|
Baseline up to 2 months
|
|
Stage of change for exercise, assessed by the Stage of Change for Exercise questionnaire (Evaluation Phase)
Time Frame: Up to 2 months
|
For the qualitative characteristics collected, univariate summaries (e.g., frequency counts and proportions) will be calculated.
For quantitative characteristics, means, standard deviations, medians, and ranges will be computed.
The analysis will be conducted as an intent-to-treat efficacy assessment comparing the two interventions.
Analyses will examine changes between baseline and follow-up scores on outcome measures by group.
Comparisons will be conducted using GEE with robust (sandwich) variance estimates.
|
Up to 2 months
|
|
Website usability, assessed by qualitative evaluation of interviews and feedback (Development Phase)
Time Frame: Up to 9 months
|
Up to 9 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Average activity level for seniors per Community Healthy Activity Model Program for Seniors (CHAMPS) questionnaire
Time Frame: Baseline up to 2 months
|
CHAMPS is a 41-item questionnaire developed by UCSF that asks about recent participation in specific physical activities and structured exercise to measure changes in physical activity level in older adults (age 65 and up).
This questionnaire estimates total weekly energy expenditure (in kilocalories per week) from low to vigorous intensity physical activities for older adults.
This physical activity survey has been used and validated with cancer survivors.
The 41-item questionnaire asks about engagement in vigorous, moderate, and light activities per week, including frequency and duration, du
|
Baseline up to 2 months
|
|
Body weight
Time Frame: Baseline up to 2 months
|
Participants will be asked to self-report their current weight in pounds.
|
Baseline up to 2 months
|
|
Measurement of exercise motivation using the Behavioral Regulation In Exercise Questionnaire (BREQ)
Time Frame: Baseline up to 2 months
|
This questionnaire concerns the reasons why a person exercises regularly, works out, or engages in other such physical activities.
It is structured so that it asks one questions and provides responses that represent external regulation, introjected regulation, identified regulation, and intrinsic motivation.
The basic issue concerns the degree to which one feels autonomous with respect to exercising or engaging in physical activity.
The BREQ measures the continuum of behavioral regulation in exercise psychology research.
The original BREQ (Mullan, Markland & Ingledew, 1997) was developed to me
|
Baseline up to 2 months
|
|
Measurement of fatigue using the Piper Fatigue Scale
Time Frame: Baseline up to 2 months
|
The Piper Fatigue Scale measures fatigue in cancer research, and includes subdomains of behavioral, affective, sensory, and cognitive/mood attributes of fatigue.
The Piper Fatigue Scale-12 is an instrument to measure the subjective dimension of fatigue, developed by BF Piper, AM Lindsey, MJ Dodd, S Ferketich, SM Paul and S Weller.
The Piper Fatigue Scale is one of the commonly used multidimensional fatigue measures in the cancer research field and includes subdomains of behavioral, affective, sensory, and cognitive/mood attributes of fatigue.
|
Baseline up to 2 months
|
|
Measurement of quality of life per European Organization for Research and Treatment of Cancer (EORTC) Quality Of Life Questionnaire-core 30 (QLQ-C30) questionnaire
Time Frame: Baseline up to 2 months
|
EORTC QLQ-C30 is a questionnaire developed to assess the quality of life of cancer patients.
The QLQ-C30 incorporates five functional scales (physical, role, cognitive, emotional, and social), three symptom scales (fatigue, pain, and nausea and vomiting), a global health status / QoL scale, and a number of single items assessing additional symptoms commonly reported by cancer patients (dyspnea, loss of appetite, insomnia, constipation and diarrhea) and perceived financial impact of the disease.
Scores range from 0-100, with higher functional scale scores indicating a higher level of healthy fu
|
Baseline up to 2 months
|
|
Self-reported physical activity assessed by the Rapid Assessment of Physical Activity (RAPA)
Time Frame: Baseline up to 2 months
|
The RAPA questionnaire was designed to provide clinicians with a tool for quickly assessing the level of physical activity of their older adult patients.
It was developed after a review and evaluation of existing written questionnaires.
The RAPA questionnaire was developed by University of Washington Health Promotion Research Center to provide clinicians with a tool for quickly assessing the level of physical activity of their older adult patients.
|
Baseline up to 2 months
|
|
Website use and acceptability assessed by questionnaire
Time Frame: Responses collected at 2 months
|
Questions about participant use and their perception of the website's features and usability will provide insights into the acceptability to revise it for further development.
This is a study specific questionnaire developed to measure the frequency of use of the websites and participant preferences about exercise.
Higher scores indicate better use and acceptance of the exercise information and website.
In addition, the questionnaire includes an open ended question for participants to provide the study team with any additional thoughts or comments about the website.
|
Responses collected at 2 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Esther Moe, OHSU Knight Cancer Institute
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB00011113 (Other Identifier: OHSU Knight Cancer Institute)
- P30CA069533 (U.S. NIH Grant/Contract)
- 11113 (DAIDS ES Registry Number)
- NCI-2016-01217 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- CPC-14128-L
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostate Carcinoma
-
M.D. Anderson Cancer CenterJanssen PharmaceuticaActive, not recruitingCastration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Aggressive Variant Prostate Carcinoma | Metastatic Prostate Neuroendocrine Carcinoma | Metastatic Prostate Small Cell CarcinomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)Active, not recruitingProstate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Recurrent Prostate Carcinoma | Metastatic Prostate Adenocarcinoma | Oligometastatic Prostate CarcinomaUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedMetastatic Prostate Carcinoma | Recurrent Prostate Carcinoma | Hormone-Resistant Prostate Cancer | Stage IV Prostate AdenocarcinomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingCastration-Resistant Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8 | Refractory Prostate Carcinoma | Metastatic Castration-Resistant Prostate CarcinomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)Active, not recruitingMetastatic Prostate Carcinoma | Prostate Adenocarcinoma | Recurrent Prostate Carcinoma | Hormone-Resistant Prostate CancerUnited States
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityActive, not recruitingCastration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Recurrent Prostate Carcinoma | Stage IV Prostate Cancer AJCC v7United States
-
University of WashingtonNational Cancer Institute (NCI)CompletedCastration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Recurrent Prostate Carcinoma | Castration Levels of Testosterone | Stage IV Prostate AdenocarcinomaUnited States
-
Sidney Kimmel Comprehensive Cancer Center at Thomas...Novartis; Prostate Cancer Clinical Trials ConsortiumTerminatedCastration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v7 | Prostate Carcinoma Metastatic in the BoneUnited States
-
Mayo ClinicCongressionally Directed Medical Research ProgramsRecruitingBiochemically Recurrent Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Locally Advanced Prostate CarcinomaUnited States
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)RecruitingBiochemically Recurrent Prostate Carcinoma | Metastatic Prostate Carcinoma | Prostate Adenocarcinoma | Stage IVB Prostate Cancer AJCC v8United States
Clinical Trials on Quality-of-Life Assessment
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedOvarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Serous Cystadenocarcinoma | Stage IV Ovarian Germ Cell Tumor | Ovarian Sarcoma | Malignant Ovarian Epithelial Tumor | Ovarian Carcinosarcoma | Ovarian Brenner Tumor | Ovarian Mucinous... and other conditionsUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedUnspecified Adult Solid Tumor, Protocol Specific | Malignant NeoplasmUnited States
-
Wake Forest University Health SciencesWithdrawnLung Metastases | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Recurrent Malignant Mesothelioma | Advanced Malignant Mesothelioma
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingMonoclonal Gammopathy of Undetermined Significance | Smoldering Plasma Cell MyelomaUnited States
-
Kantonsspital AarauRecruiting
-
Jonsson Comprehensive Cancer CenterWithdrawnInfiltrating Bladder Urothelial CarcinomaUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedBreast CarcinomaUnited States
-
Case Comprehensive Cancer CenterActive, not recruitingUnspecified Adult Solid Tumor | Tumors Metastatic to BrainUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Recruiting
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | COVID-19 InfectionUnited States